Human immunodeficiency virus 2

Summary

Alias: HIV type 2, HIV-2, Human immunodeficiency virus type 2, Human immunodeficiency virus-2, human immunodeficiency virus type 2 HIV-2, human immunodeficiency virus type 2, HIV-2, HIV, HIV2, LAV-2, AIDS virus

Top Publications

  1. pmc HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment
    Heiko Hauser
    Department of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
    Retrovirology 7:51. 2010
  2. ncbi Structural role of the secondary active domain of HIV-2 NCp8 in multi-functionality
    Takashi Matsui
    Department of Physics, School of Science, Kitasato University, 1 15 1 Kitasato, Sagamihara, Kanagawa 228 8555, Japan
    Biochem Biophys Res Commun 358:673-8. 2007
  3. doi Human immunodeficiency virus (HIV) type-1, HIV-2 and simian immunodeficiency virus Nef proteins
    Nadine Laguette
    Institut Cochin, CNRS UMR8104, Universite Paris Descartes, Paris, France
    Mol Aspects Med 31:418-33. 2010
  4. pmc Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G
    Ana Clara Ribeiro
    Instituto Superior de Ciências da Saúde Sul, Quinta da Granja, Monte da Caparica, 2829 511 Caparica, Portugal
    J Virol 79:823-33. 2005
  5. ncbi Conserved amino acids of the human immunodeficiency virus type 2 Vpx nuclear localization signal are critical for nuclear targeting of the viral preintegration complex in non-dividing cells
    Michael Belshan
    Department of Medical Microbiology and Immunology, Creighton University, Omaha, NE 68178, USA
    Virology 346:118-26. 2006
  6. ncbi Analysis of HIV-2 Vpx by modeling and insertional mutagenesis
    Lisa A Mahnke
    Department of Medicine, Divisions of Oncology and Infections Diseases, Washington University School of Medicine, PO Box 8069, 660 South Euclid Avenue, Saint Louis, MO 63110, USA
    Virology 348:165-74. 2006
  7. pmc Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release
    Beth Noble
    Department of Biochemistry and Molecular Biology, University of Southern California Keck School of Medicine, Los Angeles, USA
    J Virol 80:2924-32. 2006
  8. pmc Gag-specific CD4+ T-cell frequency is inversely correlated with proviral load and directly correlated with immune activation in infection with human immunodeficiency virus type 2 (HIV-2) but not HIV-1
    Russell B Foxall
    Unidade de Imunologia Clinica, Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Av Prof Egas Moniz, 1649 028 Lisboa, Portugal
    J Virol 82:9795-9. 2008
  9. pmc The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection
    Anna Bergamaschi
    Institut Pasteur, Unité de Régulation des Infections Rétrovirales, 25 rue du Dr Roux, 75724 Paris Cedex 15, France
    J Virol 83:4854-60. 2009
  10. pmc Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein
    Anna Le Tortorec
    Department of Infectious Disease, King s College London School of Medicine, Guy s Hospital, London SE1 9RT, United Kingdom
    J Virol 83:11966-78. 2009

Research Grants

  1. DEK EFFECTS ON GROWTH OF HEMATOPOIETIC CELLS
    Gerard Grosveld; Fiscal Year: 2002
  2. LENTIVIRAL GENE TRANSFER INTO PANCREATIC BETA-CELLS
    Mark Segal; Fiscal Year: 2003
  3. Vpr as a Mediator Proteasomal Degradation
    CARLOS M DE NORONHA; Fiscal Year: 2010
  4. PATHOGENESIS OF HIV ASSOC THROMBOTIC MICROANGIOPATHY
    CHARLES ALPERS; Fiscal Year: 2003
  5. ANTIVIRAL/BIOACTIVE COMPOUNDS--SYNTHESIS AND CHEMISTRY
    ELIAS COREY; Fiscal Year: 1999
  6. REGULATION OF HIV2 TRANSCRIPTION AND REPLICATION
    DAVID MARKOVITZ; Fiscal Year: 2002
  7. HIV-1/HIV-2 EPITOPE PROJECT, THE GAMBIA, WEST AFRICA
    Anne De Groot; Fiscal Year: 2001
  8. HIV-2--A MODEL OF HIV PRIMARY INFECTION
    Phyllis Kanki; Fiscal Year: 2002
  9. INDUCTION OF APOPTOSIS BY HIV-1 VPR
    Vicente Planelles; Fiscal Year: 2010
  10. Activation of a DNA damage pathway by HIV-1 vpr
    Vicente Planelles; Fiscal Year: 2003

Patents

  1. METHODS FOR IDENTIFYING ANTIRETROVIRAL COMPOUNDS TARGETING THE REVERSE TRANSCRIPTASE OF HIV
  2. METHODS FOR IDENTIFYING ANTIRETROVIRAL COMPOUNDS TARGETING THE REVERSE TRANSCRIPTASE OF HIV
  3. METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION
  4. METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION
  5. METHODS FOR IMPROVING AND MANAGING NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITION BASED TREATMENT
  6. DETECTION OF NUCLEIC ACIDS USING UNMODIFIED GOLD NANOPARTICLES
  7. METHODS USING TRANSFORMED YEAST CELLS FOR IMPROVING AND MANAGING NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITION BASED TREATMENT
  8. Compositions and methods for detecting human immunodeficiency virus 2 (hiv-2)
  9. Molecular scaffolds for hiv-1 immunogens
  10. DNA EXHIBITING COMPLEMENTARITY TO GENE RNA OF HUMAN IMMUNODEFICIENCY VIRUS-2 TYPE

Scientific Experts

Detail Information

Publications169 found, 100 shown here

  1. pmc HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment
    Heiko Hauser
    Department of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
    Retrovirology 7:51. 2010
    In the absence of the Vpu protein, newly formed HIV-1 particles can remain attached to the surface of human cells due to the action of an interferon-inducible cellular restriction factor, BST-2/tetherin...
  2. ncbi Structural role of the secondary active domain of HIV-2 NCp8 in multi-functionality
    Takashi Matsui
    Department of Physics, School of Science, Kitasato University, 1 15 1 Kitasato, Sagamihara, Kanagawa 228 8555, Japan
    Biochem Biophys Res Commun 358:673-8. 2007
    Nucleocapsid protein of HIV, containing two CCHC-type zinc fingers connected by a linker, is a multi-functional protein involved in many critical steps of the HIV life cycle...
  3. doi Human immunodeficiency virus (HIV) type-1, HIV-2 and simian immunodeficiency virus Nef proteins
    Nadine Laguette
    Institut Cochin, CNRS UMR8104, Universite Paris Descartes, Paris, France
    Mol Aspects Med 31:418-33. 2010
    ..multiple protein-protein interactions in which Nef is involved all contribute to explain the role played by Nef in HIV- and SIV-associated disease progression...
  4. pmc Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G
    Ana Clara Ribeiro
    Instituto Superior de Ciências da Saúde Sul, Quinta da Granja, Monte da Caparica, 2829 511 Caparica, Portugal
    J Virol 79:823-33. 2005
    Viral infectivity factor (Vif) is one of the human immunodeficiency virus (HIV) accessory proteins and is conserved in the primate lentivirus group...
  5. ncbi Conserved amino acids of the human immunodeficiency virus type 2 Vpx nuclear localization signal are critical for nuclear targeting of the viral preintegration complex in non-dividing cells
    Michael Belshan
    Department of Medical Microbiology and Immunology, Creighton University, Omaha, NE 68178, USA
    Virology 346:118-26. 2006
    The HIV-2 viral accessory protein Vpx is related to, but distinct from the Vpr protein of HIV-1...
  6. ncbi Analysis of HIV-2 Vpx by modeling and insertional mutagenesis
    Lisa A Mahnke
    Department of Medicine, Divisions of Oncology and Infections Diseases, Washington University School of Medicine, PO Box 8069, 660 South Euclid Avenue, Saint Louis, MO 63110, USA
    Virology 348:165-74. 2006
    Vpx facilitates HIV-2 nuclear localization by a poorly understood mechanism. We have compared Vpx to an NMR structure HIV-1 Vpr in a central helical domain and probed regions of Vpx by insertional mutagenesis...
  7. pmc Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release
    Beth Noble
    Department of Biochemistry and Molecular Biology, University of Southern California Keck School of Medicine, Los Angeles, USA
    J Virol 80:2924-32. 2006
    The envelope (Env) protein of human immunodeficiency virus type 2 (HIV-2) and the HIV-1 Vpu protein stimulate the release of retroviral particles from human cells that restrict virus production, an activity that we call the enhancement ..
  8. pmc Gag-specific CD4+ T-cell frequency is inversely correlated with proviral load and directly correlated with immune activation in infection with human immunodeficiency virus type 2 (HIV-2) but not HIV-1
    Russell B Foxall
    Unidade de Imunologia Clinica, Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Av Prof Egas Moniz, 1649 028 Lisboa, Portugal
    J Virol 82:9795-9. 2008
    b>Human immunodeficiency virus type 2 (HIV-2) infection, unlike HIV-1 infection, is normally characterized by low rates of CD4 depletion and low-to-undetectable viremia...
  9. pmc The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection
    Anna Bergamaschi
    Institut Pasteur, Unité de Régulation des Infections Rétrovirales, 25 rue du Dr Roux, 75724 Paris Cedex 15, France
    J Virol 83:4854-60. 2009
    The human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) genomes encode several auxiliary proteins that have increasingly shown their importance in the virus-host relationship...
  10. pmc Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein
    Anna Le Tortorec
    Department of Infectious Disease, King s College London School of Medicine, Guy s Hospital, London SE1 9RT, United Kingdom
    J Virol 83:11966-78. 2009
    ..While human immunodeficiency virus type 1 (HIV-1) encodes the accessory gene vpu to overcome the action of tetherin, the lineage of primate lentiviruses that gave ..
  11. pmc Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase
    Rebecca D Powell
    Department of Biochemistry, Wake Forest School of Medicine, Winston Salem, North Carolina 27157, USA
    J Biol Chem 286:43596-600. 2011
    The SAMHD1 protein is an HIV-1 restriction factor that is targeted by the HIV-2 accessory protein Vpx in myeloid lineage cells...
  12. pmc Efficient Nef-mediated downmodulation of TCR-CD3 and CD28 is associated with high CD4+ T cell counts in viremic HIV-2 infection
    Mohammad Khalid
    Institute of Molecular Virology, University Clinic of Ulm, Ulm, Germany
    J Virol 86:4906-20. 2012
    The role of the multifunctional accessory Nef protein in the immunopathogenesis of HIV-2 infection is currently poorly understood...
  13. doi A novel DCAF1-binding motif required for Vpx-mediated degradation of nuclear SAMHD1 and Vpr-induced G2 arrest
    Wei Wei
    First Hospital of Jilin University, Institute of Virology and AIDS Research, Changchun, Jilin Province, China
    Cell Microbiol 14:1745-56. 2012
    b>HIV-2 and closely related SIV Vpx proteins are essential for viral replication in macrophages and dendritic cells. Vpx hijacks DCAF1-DDB1-Cul4 E3 ubiquitin ligase to promote viral replication...
  14. pmc HIV-2 and SIVmac accessory virulence factor Vpx down-regulates SAMHD1 enzyme catalysis prior to proteasome-dependent degradation
    Maria Delucia
    Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15260, USA
    J Biol Chem 288:19116-26. 2013
    ..triphosphohydrolase, down-regulates dNTP pools in terminally differentiated and quiescent cells, thereby inhibiting HIV-1 infection at the reverse transcription step...
  15. pmc Evolutionary toggling of Vpx/Vpr specificity results in divergent recognition of the restriction factor SAMHD1
    Oliver I Fregoso
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS Pathog 9:e1003496. 2013
    SAMHD1 is a host restriction factor that blocks the ability of lentiviruses such as HIV-1 to undergo reverse transcription in myeloid cells and resting T-cells...
  16. pmc Current CDC efforts to prevent and control human immunodeficiency virus infection and AIDS in the United States through information and education
    J O Mason
    Centers for Disease Control (CDC, Atlanta, GA 30333
    Public Health Rep 103:255-60. 1988
    ..for AIDS information and education efforts are those who are at increased risk of acquiring or transmitting the AIDS virus because they use illicit intravenous drugs and share needles, engage in anal intercourse, have many sexual ..
  17. ncbi [Present state of countermeasure to AIDS in the world today]
    E Takakuwa
    Hokkaido University
    Kansenshogaku Zasshi 71:1097-107. 1997
    1. Introduction: Only about 10 years have passed since HIV was discovered but WHO presumes that there will be 30 to 40 million infected cases by the year 2,000...
  18. pmc Support for hospital-based HIV testing and counseling: a national survey of hospital marketing executives
    J A Boscarino
    Department of Epidemiology and Biostatistics, University of California at San Francisco 94105, USA
    Public Health Rep 110:467-75. 1995
    ..Control and Prevention (CDC) estimated that routine testing of hospital patients for human immunodeficiency virus (HIV) could identify more than 100,000 patients with previously unrecognized HIV infections...
  19. ncbi Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis
    Myriam Witvrouw
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    Antivir Ther 9:57-65. 2004
    Limited information is available on the activity of antiretroviral drugs against human immunodeficiency virus type 2 (HIV-2) and simian immunodeficiency virus (SIV) strains to guide their use in treatment or prophylaxis...
  20. pmc Integrating reproductive health: myth and ideology
    L Lush
    Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, England
    Bull World Health Organ 77:771-7. 1999
    Since 1994, integrating human immunodeficiency virus/sexually transmitted disease (HIV/STD) services with primary health care, as part of reproductive health, has been advocated to address two major public health problems: to control the ..
  21. pmc An insight into Dupuytren's contracture
    G A Murrell
    Division of Orthopaedic Surgery, Duke University Medical Center, Durham, NC 27710
    Ann R Coll Surg Engl 74:156-60; discussion 161. 1992
    ..a hereditary predisposition and has strong associations with diabetes, alcohol consumption, cigarette smoking and HIV infection...
  22. ncbi Association between carriage of oral yeasts, malnutrition and HIV-1 infection among Tanzanian children aged 18 months to 5 years
    F Scheutz
    Department of Oral Epidemiology and Public Health, Faculty of Health Sciences, Aarhus University, Denmark
    Community Dent Oral Epidemiol 25:193-8. 1997
    The objective was to determine whether there is an association between carriage of oral yeasts, malnutrition and HIV-1 infection among Tanzanian children...
  23. ncbi [Cardiac side effects of anti-HIV agents]
    J J Monsuez
    , , Villejuif
    Arch Mal Coeur Vaiss 93:835-40. 2000
    ..nature and prognosis of cardiac complications occurring in patients infected by the Human Immunodeficiency Virus-1 (HIV-1) have changed considerably since the introduction of highly acive and anti-retroviral triple therapy ("HART")...
  24. ncbi Evaluating HIV-infected patients with headache: who needs computed tomography?
    A L Gifford
    Health Services Research and Development Program, VA San Diego Calif Healthcare System and the Department of Medicine, University of California San Diego School of Medicine, La Jolla, USA
    Headache 41:441-8. 2001
    To empirically test a clinical prediction rule for evaluating HIV-infected patients complaining of headache and to identify those at low risk for intracranial mass lesion who do not need immediate computed tomography of the head.
  25. pmc HIV and AIDS: where is the epidemic going?
    T E Mertens
    Division of Development of Policy, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 74:121-9. 1996
    Routine surveillance of HIV (human immunodeficiency virus) infection and AIDS has been established over the past decade in many countries around the world...
  26. pmc Projections of HIV infections and AIDS cases to the year 2000
    J Chin
    Global Programme on AIDS, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 68:1-11. 1990
    ..acquired immunodeficiency syndrome) in the early 1980s, uncertainty about the present and future dimensions of HIV (human immunodeficiency virus) infection led to the development of many models to estimate current and future ..
  27. pmc Delays in protease inhibitor use in clinical practice
    K M Fairfield
    Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Mass. 02215, USA
    J Gen Intern Med 14:395-401. 1999
    ..PATIENTS: One hundred ninety patients living with HIV and a viral load of more than 10,000 copies/ml...
  28. ncbi [Strip immunoblot assay (SIA) with recombinant antigens and synthetic peptide for detection of anti HIV-1 and HIV-2 antibodies]
    M Deguchi
    Laboratory for Clinical Investigatio, Osaka University Hospital
    Kansenshogaku Zasshi 75:371-81. 2001
    The serodiagnosis of human immunodeficiency virus (HIV) infection has widely been established by the screening test and the confirmatory test. At present, Western blot (WB) assay is mostly used as the confirmatory test...
  29. ncbi Women's disclosure of HIV status: experiences of mistreatment and violence in an urban setting
    A C Gielen
    Johns Hopkins University, School of Public Health, Department of Health Policy and Management, Baltimore, MD 21205, USA
    Women Health 25:19-31. 1997
    ..proportion of AIDS cases and anecdotal reports suggest some face substantial risks when others learn they are HIV-positive...
  30. pmc The HIV antibody test: why gay and bisexual men want or do not want to know their results
    D W Lyter
    University of Pittsburgh, Department of Medicine, School of Medicine
    Public Health Rep 102:468-74. 1987
    ..of the Multicenter AIDS Cohort Study (MACS), were invited by mail to learn the results of their antibody test for HIV infection--human immunodeficiency virus infection...
  31. pmc PHS grants for minority group HIV infection education and prevention efforts
    J Bowles
    University of Pennsylvania
    Public Health Rep 104:552-9. 1989
    ..OMH added HIV infection to the six health priority areas after epidemiologic data showed that the representation of blacks and ..
  32. ncbi [Pulmonary function tests after pneumocystis carinii pneumonia in HIV infected patients]
    G Pothoff
    ,
    Pneumologie 46:221-5. 1992
    Significant impairment of lung volumes and gas exchange in HIV-infected patients with acute Pneumocystis carinii pneumonia (PCP) has been reported, whereas little is known about lung function compromise following successful therapy...
  33. pmc Teen Peer Outreach-Street Work Project: HIV prevention education for runaway and homeless youth
    G D Podschun
    College of Health and Human Services, San Diego State University, CA
    Public Health Rep 108:150-5. 1993
    ..Homeless young people are commonly involved in one or more of the following activities that place them at risk for HIV infection--unprotected sexual intercourse, needle-sharing in the use of injectable drugs, sex with someone who ..
  34. pmc HIV risk differences between African-American and white men who have sex with men
    T G Heckman
    Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee 53226, USA
    J Natl Med Assoc 91:92-100. 1999
    ..men who have sex with men remain at disproportionately greater risk for contracting human immunodeficiency virus (HIV) infection...
  35. pmc What is the significance of black-white differences in risky sexual behavior?
    E H Johnson
    Department of Family Medicine, Morehouse School of Medicine, Atlanta, Georgia 30331 2099
    J Natl Med Assoc 86:745-59. 1994
    ..While whites reported a greater use of drugs and a significantly higher level of knowledge about HIV/AIDS, African Americans reported a significantly greater perception of risk for being exposed to human ..
  36. pmc Clinic HIV-focused features and prevention of Pneumocystis carinii pneumonia
    B J Turner
    Center for Research in Medical Education and Health Care, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107-5083, USA
    J Gen Intern Med 13:16-23. 1998
    OBJECTIVE: To examine the association of clinic HIV-focused features and advanced HIV care experience with Pneumocystis carinii pneumonia (PCP) prophylaxis and development of PCP as the initial AIDS diagnosis...
  37. pmc HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors
    V E Stone
    Department of Medicine, Memorial Hospital of Rhode Island, Pawtucket 02860, USA
    J Gen Intern Med 13:586-93. 1998
    OBJECTIVE: To gather qualitative data regarding HIV/AIDS patients' perspectives about HIV-1 protease inhibitors (PIs), and about their experiences taking and adhering to regimens containing PIs...
  38. pmc Pilot study of AIDS risk in the general population
    R W Jeffery
    Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis 55454-1015
    Public Health Rep 107:105-9. 1992
    ..for obtaining information on the prevalence of risk behaviors for human immunodeficiency virus infection (HIV) in the general population...
  39. ncbi Dental care of infectious patients in Denmark, 1986-1993: theoretical considerations and empirical findings
    F Scheutz
    Department of Oral Epidemiology and Public Health, Royal Dental College, Faculty of Health Sciences, Aarhus University, Denmark
    Community Dent Oral Epidemiol 23:226-31. 1995
    Changes in infection control and behavior and attitudes towards HIV-infected patients from 1986 to 1992/93 were studied among a random sample of 335 Danish dentists; previous studies among random samples of Danish dentists served as ..
  40. pmc Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates
    A Kane
    Trinity College, Duke University, Durham, NC, USA
    Bull World Health Organ 77:801-7. 1999
    ..estimates of the number of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections that may occur from unsafe injections in the developing world...
  41. pmc Transmission of HIV, hepatitis B virus, and other bloodborne pathogens in health care settings: a review of risk factors and guidelines for prevention. World Health Organization
    D J Hu
    Global Programme on AIDS, World Health Organization, Geneva, Switzerland
    Bull World Health Organ 69:623-30. 1991
    Recent reports of the transmission of human immunodeficiency virus (HIV) in health care settings have caused considerable public health concern...
  42. ncbi Linear epitopes of HIV-1, presented as hybrids with Escherichia coli beta-galactosidase or synthetic peptides
    M G Isaguliants
    D.I. Ivanovsky Institute of Virology, Academy of Medical Sciences, Moscow, Russia
    AIDS Res Hum Retroviruses 10:655-64. 1994
    b>HIV-1 B cell epitopes from gp41, the T cell epitope of p34pol, and a cluster of B and T epitopes from p17gag were selected...
  43. pmc An assessment of Ryan White Title IIIb HIV early intervention programs in Region VI of the United States Public Health Service
    M K Rawlings
    Community Oriented Primary Care Program of Parkland Memorial Hospital, Dallas, Texas, USA
    J Natl Med Assoc 87:436-40. 1995
    ..in Region VI of the United States Public Health Service (USPHS) to determine when human immunodeficiency virus (HIV)-infected clients assessed care...
  44. ncbi The effects of HIV viral load on the phagocytic activity of monocytes activated with lipopolysaccharide from oral microorganisms
    A A Baqui
    Department of Oral Medicine, Dental School, University of Maryland, Baltimore 21201, USA
    Immunopharmacol Immunotoxicol 21:421-38. 1999
    A study was undertaken to determine whether viral load status in HIV+ patients has any potential effect on monocyte phagocytic function both before and after challenge of the monocytes with lipopolysaccharide (LPS) isolated from oral ..
  45. ncbi Significant anti-HIV activity of new modified polyanionic polymers in vitro
    R W Buckheit
    Southern Research Institute, Birmingham, Alabama
    Immunopharmacol Immunotoxicol 14:707-21. 1992
    The anti-HIV activities of two new polyanionic polymers (AM 242 and AM 612) were investigated in cell culture-based and biochemical antiviral assays...
  46. pmc Comparative evaluation of 36 commercial assays for detecting antibodies to HIV
    I Van Kerckhoven
    Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belgium
    Bull World Health Organ 69:753-60. 1991
    ..of 36 commercially available assays for detection of antibodies to human immunodeficiency virus type 1 (HIV-1) and/or type 2 (HIV-2)...
  47. pmc Epidemic human immunodeficiency virus (HIV) infection among intravenous drug users (IVDU)
    A B Williams
    Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510
    Yale J Biol Med 60:545-67. 1987
    Human immunodeficiency virus (HIV) infection is epidemic among intravenous drug users (IVDU), particularly in the northeastern United States...
  48. ncbi [Improved prognosis of first episode HIV associated Pneumocystis carinii pneumonia without preventive treatment: etiology and sequelae]
    S Ewig

    Pneumologie 50:455-61. 1996
    OBJECTIVE: The prognosis of first episodes of HIV-associated PCP has markedly improved. The knowledge about the reasons for this progress could bear important implications for the management of HIV-infected patients...
  49. pmc A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali
    R T Perry
    Department of Pediatrics, University of Maryland School of Medicine, Baltimore, USA
    Bull World Health Organ 76:63-71. 1998
    ..vaccine had not been evaluated in sub-Saharan Africa or on individuals infected with human immunodeficiency virus (HIV)...
  50. pmc Maintaining confidentiality in a look-back investigation of patients treated by a HIV-infected dentist
    P M Arnow
    Department of Medicine, University of Chicago Hospitals, IL 60637
    Public Health Rep 108:273-8. 1993
    The spread of human immunodeficiency virus (HIV) from a Florida dentist with acquired immunodeficiency syndrome (AIDS) to several of his patients has generated considerable concern about the risk of HIV transmission during dental ..
  51. ncbi [Subtype and sequence analysis of the C2-V3 region of gp120 genes among human immunodeficiency virus infected IDUs in Ruili epidemic area of Yunnan Province of China]
    Y Guan
    Institute of Virology, Chinese Academy of Preventive Medicine, Beijing 100052
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 11:8-12. 1997
    DNA fragments of HIV-1 env gene were amplified by nested-PCR from 17 uncultured peripheral blood mononuclear cells (PBMCs) obtained from HIV-1 seropositive intravenous drug users (IDUs) in Ruili city of Yunnan Province...
  52. ncbi Optimal management strategies for HIV-infected patients who present with cough or dyspnea: a cost-effective analysis
    K A Freedberg
    Section of General Internal Medicine, Boston City Hospital, Boston University School of Medicine, Massachusetts 02118
    J Gen Intern Med 7:261-72. 1992
    ..and costs of alternative management strategies for patients infected with the human immunodeficiency virus (HIV) who present with pulmonary symptoms...
  53. ncbi Predicting cutaneous hypersensitivity reactions to cotrimoxazole in HIV-infected individuals receiving primary Pneumocystis carinii pneumonia prophylaxis
    S Hennessy
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104-6095, USA
    J Gen Intern Med 10:380-6. 1995
    ..DESIGN: Retrospective cohort study. SETTING: One university-based outpatient HIV clinic and one university-affiliated internal medicine and infectious disease medical practice...
  54. pmc Unsafe injections in the developing world and transmission of bloodborne pathogens: a review
    L Simonsen
    World Health Organization, Geneva, Switzerland
    Bull World Health Organ 77:789-800. 1999
    ..The transmissibility of hepatitis B and C viruses and human immunodeficiency virus (HIV) was estimated using data from studies of needle-stick injuries...
  55. ncbi [Evaluation of an HIV screening assay kit for the combined detection of anti-HIV-1/2 antibodies and HIV p24 antigen]
    T Shima
    Department of Virology, Kanagawa Prefectural Public Health Laboratory, Yokohama City University Hospital, School of Medicine
    Kansenshogaku Zasshi 75:1014-24. 2001
    We have evaluated a new HIV screening assay kit (Genscreen HIV Ag-Ab) for the HIV antigen-antibody combined test by comparing with two HIV antigen-antibody combined assay kits (VIDAS HIV DUO, Enzygnost HIV integral)...
  56. pmc Infection by HIV-1 blocked by binding of dextrin 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T-cells
    S Shaunak
    Department of Infectious Diseases, Royal Postgraduate Medical School, London
    Br J Pharmacol 113:151-8. 1994
    ..a sulphated polysaccharide, dextrin sulphate, were synthesized and tested for their ability to block infection by HIV-1. Using the T-cell lines, C8166 and HPB-ALL, and the laboratory adapted strains of HIV-1.MN, HIV-1.IIIb and HIV-1...
  57. pmc Reproductive tract infections, gynaecological morbidity and HIV seroprevalence among women in Mumbai, India
    L Brabin
    Liverpool School of Tropical Medicine, England
    Bull World Health Organ 76:277-87. 1998
    ..contribution to pelvic inflammatory disease (PID), as well as the seroprevalence of human immunodeficiency virus (HIV), among women living in three inner city wards of Mumbai, India...
  58. pmc Natural history of HIV-1 infection and predictors of survival in a cohort of HIV-1 seropositive injecting drug users
    L S Brown
    Division of Medical Services, Evaluation and Research, Addiction Research and Treatment Corporation, Brooklyn, New York 11201, USA
    J Natl Med Assoc 88:37-42. 1996
    ..This article describes the natural history of human immunodeficiency virus (HIV) disease in a New York City cohort of 328 HIV-infected injecting drug users...
  59. ncbi An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi
    F H Verhoeff
    Liverpool School of Tropical Medicine
    Ann Trop Med Parasitol 92:141-50. 1998
    ..8 v. 9.5 g/dl; P < 0.001). Of the 233 women tested for HIV infection, 18.8% of the primigravidae and 23.7% of the multigravidae were seropositive...
  60. pmc HIV risk screening in the primary care setting. Assessment of physicians skills
    M D Wenrich
    Department of Medicine, University of Washington, Seattle 98195-6420, USA
    J Gen Intern Med 12:107-13. 1997
    OBJECTIVE: To assess the content and extent of HIV risk assessment by primary care physicians across a diverse panel of patients with unidentified HIV risk behaviors...
  61. ncbi [Evaluation of a new screening assay kit for the combined detection of HIV p24 antigen and antibody--comparison of the performance of the new kit and HIV antibody assay kits]
    T Hayashi
    Department of Virology, Kanagawa Prefectural Public Health Laboratory
    Kansenshogaku Zasshi 73:681-8. 1999
    DUO is an automated HIV infection screening test kit based on the combined detection of p24 Ag and anti-HIV-1 and anti-HIV-2 IgG in human sera or plasma using the ELFA technique (Enzyme-Linked Fluorescent Assay)...
  62. ncbi Production of monoclonal antibodies to human immunodeficiency virus type-2
    A M Diaz
    Department of Microbiology and Medical Zoology, School of Medicine, University of Puerto Rico, San Juan 00936 5067
    P R Health Sci J 11:129-34. 1992
    The ROD strain of the human immunodeficiency virus type 2 (HIV-2) was used to produce monoclonal antibodies. Virus grown in CEM cells was partially purified by ultracentrifugation and solubilized in a buffer containing Triton X-100...
  63. ncbi Pediatric HIV-1 infection: a clinical overview
    G B Scott
    Division of Pediatric Infectious Disease and Immunology, University of Miami School of Medicine, Florida
    Pediatr Dermatol 9:323-5. 1992
    ..including the timing of perinatal transmission, maternal factors predisposing to perinatal transmission of HIV-1, the best methods for early diagnosis in the neonate, and means of preventing perinatal HIV-1 infection...
  64. pmc HIV disease as a cause of death for African Americans in 1987 and 1990
    D K Smith
    Dept of Public Health Policy and Administration, School of Public Health, University of Michigan, Ann Arbor
    J Natl Med Assoc 84:481-7. 1992
    ..data for 1987 and 1988 from the National Center for Health Statistics, combined with human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) surveillance data through December 1990 from the Centers for Disease ..
  65. pmc Retroviral infections transmitted by blood transfusion
    S G Sandler
    Georgetown University School of Medicine, Washington, DC
    Yale J Biol Med 63:353-60. 1990
    Modifications in donor screening and the introduction of laboratory testing of donated blood for anti-HIV-1 and anti-HTLV-I have resulted in a significant reduction in the risks of retroviral infections from blood transfusion...
  66. pmc Death, AIDS morbidity, and HIV seroprevalence in New York City intravenous drug abusers
    W Burkett
    Division of Evaluation and Medical Affairs, Addiction Research and Treatment Corporation, Brooklyn, New York 11201
    J Natl Med Assoc 82:777-80. 1990
    ..was established in 1985 among drug treatment clinics in New York City to monitor the human immunodeficiency virus (HIV) epidemic. HIV seroprevalence was 54% (255/469) in 1985, 61% (159/262) in 1986, and 60% (133/222) in 1987...
  67. pmc The role of the FDA in the effort against AIDS
    F E Young
    Office of Public Affairs, Rockville, MD 20857
    Public Health Rep 103:242-5. 1988
    ..the agency quickly evaluated and approved ELISA and Western blot diagnostic kits for detecting the presence of HIV antibody. These test kits have made an important contribution to safeguarding the nation's blood supply...
  68. ncbi Alcohol consumption among HIV-infected patients
    F Lefevre
    Division of General Internal Medicine, Northwestern University Medical School, Chicago, Illinois 60611, USA
    J Gen Intern Med 10:458-60. 1995
    ..cohort study analyzed the prevalence of alcoholism and patterns of alcohol intake over time in a cohort of HIV-infected patients, predominantly homosexual/bisexual men...
  69. ncbi [Reverse transcriptase gene analysis of HIV-1 mutants cultured in the presence of AZT]
    M Kondo
    Department of Virology, Kanagawa Prefectural Public Health Laboratories
    Kansenshogaku Zasshi 67:992-7. 1993
    b>HIV-1 strains were isolated from four patients treated with AZT for more than 6 months and from three patients untreated with AZT...
  70. ncbi [Sexually transmitted disease infection in HIV carriers]
    K Ishikawa
    Yamanashi Institute for Public Health
    Kansenshogaku Zasshi 68:474-8. 1994
    Heterosexual transmission of the human immunodeficiency virus (HIV) appears to occur readily all over the world. Recent reports have suggested an association between HIV and sexually transmitted disease (STD)...
  71. ncbi [Investigation of AZT sensitivity of HIV-1 isolates from patients treated with AZT]
    T Saito
    Department of Virology, Kanagawa Prefectural Public Health Laboratories
    Kansenshogaku Zasshi 67:311-4. 1993
    AZT sensitivity was investigated on 6 HIV-1 isolates by culture method. Three of the isolates derived from 2 patients treated with AZT and the others were isolated from patients not treated with AZT...
  72. pmc Short-term declines in CD4 levels associated with cocaine use in HIV-1 seropositive, minority injecting drug users
    N S Siddiqui
    Division of Medical Services, Evaluation and Research, Addiction Research and Treatment Corporation, Brooklyn, New York 11201
    J Natl Med Assoc 85:293-6. 1993
    ..the association of cocaine use with short-term change in CD4 counts among human immunodeficiency virus type 1 (HIV-1) seropositive, minority injecting drug users prior to the introduction of zidovudine (AZT)...
  73. pmc The acceptability of the female condom among low-income African-American women
    D O Shervington
    Department of Psychiatry, Louisiana State University Medical Center, New Orleans 70112 2822
    J Natl Med Assoc 85:341-7. 1993
    Among women, African Americans are at the highest risk for contracting the human immunodeficiency virus (HIV)...
  74. ncbi [Prognosis and evaluation of drug therapy by V3 and RT gene analysis of HIV-1]
    M Morimoto
    Osaka Prefectural Institute of Public Health, Japan
    Kansenshogaku Zasshi 70:347-53. 1996
    We have reported on the investigation of 54 HIV-1 patients concerning the isolation and clinical marker in the preceding paper. We have attempted the analysis of the V3 and RT genes...
  75. pmc Preferred sources of AIDS information, risk perceptions, and risk behaviors among inner-city community college students
    J A Rich
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Natl Med Assoc 88:87-93. 1996
    ..of acquired immunodeficiency syndrome (AIDS) information and level of worry about human immunodeficiency virus (HIV) among community college students, a survey of 102 students in an inner-city community college was conducted...
  76. pmc Effects of incarceration on HIV-infected individuals
    M M Griffin
    Department of Family Practice and Community Medicine, University of Texas Houston Medical School, Houston, Texas and Stony Brook, New York 77030, USA
    J Natl Med Assoc 88:639-44. 1996
    Human immunodeficiency virus (HIV) infection is a critical problem among the incarcerated population, with rates as high as 17% being reported for prison systems in New York...
  77. pmc Clinic services for persons with AIDS. Experience in a high-prevalence state
    L E Markson
    Center for Research in Medical Education and Health Care, Jefferson Medical College, Philadelphia, PA, USA
    J Gen Intern Med 12:141-9. 1997
    OBJECTIVE: To profile characteristics of clinics caring for persons with advanced HIV infection. DESIGN AND SETTING: Survey of clinic directors in New York State...
  78. pmc A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4
    A McKnight
    Section of Virology, Chester Beatty Laboratories, Institute of Cancer Research, London, United Kingdom
    J Virol 72:4065-71. 1998
    Like human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV), HIV-2 requires a coreceptor in addition to CD4 for entry into cells...
  79. ncbi Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast
    D Pieniazek
    Division of AIDS, STD, and TB Laboratory Research, National Centers for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    AIDS Res Hum Retroviruses 15:603-8. 1999
    We analyzed the genetic variability and phylogenetic relationships among 28 HIV-2 strains collected from patients enrolled in an HIV epidemiologic study in Abidjan, Ivory Coast, during 1995-1996...
  80. ncbi Multifactorial analysis of exchanger efficiency and liquid conservation during perfluorochemical liquid-assisted ventilation
    M R Wolfson
    Department of Physiology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA
    Biomed Instrum Technol 33:260-7. 1999
    ..Because PFC liquid loss occurs with all current means of oxygenating and removing CO2, this study raises the importance of developing alternative, bulk-gas-flow-independent, means to recondition PFC liquids...
  81. ncbi Facilitators and barriers to use of the female condom: qualitative interviews with women of diverse ethnicity
    K H Choi
    University of California San Francisco, Center for AIDS Prevention Studies, 94105, USA
    Women Health 30:53-70. 1999
    Women in the United States, particularly African-Americans and Hispanics, are at increased risk for HIV. The female condom now offers women a potentially important option for HIV prevention, yet few efforts have been made to increase its ..
  82. ncbi [Neuropsychological evaluation of the cognitive deficits in infection by human immunodeficiency virus type 1 (HIV-1)]
    L Clemente Millana
    , , Universidad Complutense de Madrid, Madrid,
    Rev Neurol 31:1192-201. 2000
    INTRODUCTION: In addition to its ability to infect immune system cells, the human immunodeficiency virus type-1 (HIV-1), possesses neurotropism, that is, the virus is able to enter the central nervous system, even in patients without ..
  83. ncbi Sup35p yeast prion-like protein as an adapter for production of the Gag-p55 antigen of HIV-1 and the L-chain of botulinum neurotoxin in Saccharomyces cerevisiae
    P A Ivanov
    V M Stepanov Laboratory of Protein Chemistry, GNIlgenetika, Moscow, Russia
    Res Microbiol 152:27-35. 2001
    Effective expression of the HIV-1 core protein Gag-p55 was obtained in Saccharomyces cerevisiae under control of the inducible UASgal/CYC1 promoter as a translational fusion with the prion-forming NM domain of the translation terminator ..
  84. ncbi [Association of peripheral facial paralysis in patients with human immunodeficiency virus infection]
    P Casanova Sotolongo
    , Beira, Mozambique
    Rev Neurol 32:327-30. 2001
    INTRODUCTION: Neurological disorders are common in patients infected with the human immunodeficiency virus (HIV)...
  85. pmc Tsg101, an inactive homologue of ubiquitin ligase e2, interacts specifically with human immunodeficiency virus type 2 gag polyprotein and results in increased levels of ubiquitinated gag
    Erin L Myers
    Department of Medicine, Addenbrooke s Hospital, Cambridge CB2 2QQ, United Kingdom
    J Virol 76:11226-35. 2002
    ..a yeast two-hybrid screen of a T-cell cDNA library to identify cellular proteins that interact with human immunodeficiency virus type 2 (HIV-2) Gag polyprotein, we identified Tsg101, an inactive homologue of ubiquitin ligase E2...
  86. ncbi Sequential modification of translation initiation factor eIF4GI by two different foot-and-mouth disease virus proteases within infected baby hamster kidney cells: identification of the 3Cpro cleavage site
    Rebecca Strong
    Institute for Animal Health, Pirbright, Woking, Surrey GU24 0NF, UK
    J Gen Virol 85:2953-62. 2004
    ..about 40 aa) of the protein, between the sites cleaved by the poliovirus 2A protease and the human immunodeficiency virus type 2 protease. Human eIF4GI was found to be resistant to the action of the FMDV 3C protease...
  87. pmc Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene
    Sabelle Jallow
    Medical Research Council Laboratories, Banjul, The Gambia
    J Clin Microbiol 45:1565-71. 2007
    b>Human immunodeficiency virus type 2 (HIV-2) is naturally resistant to several antiretroviral drugs, including all of the non-nucleoside reverse transcriptase inhibitors and the entry inhibitor T-20, and may have reduced susceptibility to ..
  88. pmc Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006
    Florence Damond
    APHP, Hopital Bichat Claude Bernard, Laboratoire de Virologie, Paris, 75018 France
    J Clin Microbiol 46:2088-91. 2008
    b>Human immunodeficiency virus type 2 (HIV-2) RNA quantification assays used in nine laboratories of the ACHI(E)V(2E) (A Collaboration on HIV-2 Infection) study group were evaluated...
  89. pmc Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma
    Katie L Davis
    Department of Microbiology, University of Alabama at Birmingham, 720 20th Street South, Kaul 816, Birmingham, AL 35294, USA
    J Virol 83:1240-59. 2009
    Deciphering antibody specificities that constrain human immunodeficiency virus type 1 (HIV-1) envelope (Env) diversity, limit virus replication, and contribute to neutralization breadth and potency is an important goal of current HIV/..
  90. ncbi HIV1 V3 loop hypermutability is enhanced by the guanine usage bias in the part of env gene coding for it
    Vladislav Victorovich Khrustalev
    Department of General Chemistry, Belarussian State Medical University, Minsk 220000, Belarus
    In Silico Biol 9:255-69. 2009
    ..that nucleotide sequences of env genes coding for third variable regions (V3 loops) of gp120 from HIV1 and HIV2 have different kinds of guanine usage biases...
  91. pmc Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir
    Danielle Perez Bercoff
    Laboratoire de Retrovirologie, CRP Sante, Luxembourg, Luxembourg
    Retrovirology 7:98. 2010
    b>Human Immunodeficiency Virus type 2 is naturally resistant to some antiretroviral drugs, restricting therapeutic options for patients infected with HIV-2...
  92. doi Detection, quantification, and characterisation of HIV/SIV
    Neil Berry
    Division of Cellular and Molecular Medicine, Centre for Infection, St George s University of London, London, UK
    Methods Mol Biol 665:133-60. 2011
    Selected techniques for the detection, quantification, and characterisation of HIV1, HIV2, and SIV, as applied to diagnostic and research purposes, are described...
  93. doi Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool
    Benoit Visseaux
    Laboratoire de Virologie, Assistance Publique Hopitaux de Paris, Hopital Bichat Claude Bernard, France
    J Infect Dis 205:111-20. 2012
    The use of CCR5 inhibitors requires a tool to predict human immunodeficiency virus type 2 (HIV-2) tropism, as established in HIV-1. The aim of our study was to identify genotypic determinants of HIV-2 tropism located in the gp105 V3 loop.
  94. pmc Electrostatic potential of human immunodeficiency virus type 2 and rhesus macaque simian immunodeficiency virus capsid proteins
    Katarzyna Bozek
    Max Planck Institute for Informatics Saarbrücken, Germany
    Front Microbiol 3:206. 2012
    b>Human immunodeficiency virus type 2 (HIV-2) and simian immunodeficiency virus isolated from a macaque monkey (SIVmac) are assumed to have originated from simian immunodeficiency virus isolated from sooty mangabey (SIVsm)...
  95. pmc Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform
    Ming Chang
    Department of Laboratory Medicine, Division of Virology, University of Washington, Seattle, United States
    J Clin Virol 55:128-33. 2012
    Optimal care of persons infected with human immunodeficiency virus type 2 (HIV-2) requires an accurate assessment of HIV-2 plasma viral load (VL), but no clinically approved quantitative HIV-2 RNA VL assay exists.
  96. pmc Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens
    Robert A Smith
    Department of Pathology, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 7:e45372. 2012
    b>Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors and exhibits reduced susceptibility to several of the protease inhibitors used for antiretroviral therapy of HIV-1...
  97. doi Multiple platforms of a HIV-2 derived lentiviral vector for expanded utility
    Ajit G Chande
    Virology Laboratory, Advanced Centre for Treatment, Research and Education in Cancer ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India
    Plasmid 69:90-5. 2013
    Using the Indian Human immunodeficiency virus type 2 (HIV-2) isolate derived lentiviral vector (LV) system reported earlier, we have derived multiple differently configured transfer vectors...
  98. pmc The efficiency of Vpx-mediated SAMHD1 antagonism does not correlate with the potency of viral control in HIV-2-infected individuals
    Hangxing Yu
    Institute of Molecular Virology, Ulm University Medical Center, Ulm 89081, Germany
    Retrovirology 10:27. 2013
    The presence of a vpx gene distinguishes HIV-2 from HIV-1, the main causative agent of AIDS...
  99. pmc A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilization
    Christopher Bohl
    Nebraska Center for Virology, University of Nebraska Lincoln, Lincoln, Nebraska, United States of America
    PLoS ONE 8:e69406. 2013
    ..residues at 183 and 191 ("twin cysteines") is present in several simian immunodeficiency viruses, human immunodeficiency virus type 2 (HIV-2) and some SIV(cpz) lineages, but not in HIV-1...
  100. doi Human immunodeficiency virus type 2 infections in Austria
    Ninon Taylor
    Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Hospital Salzburg, Muellner Hauptstrasse 48, 5020, Salzburg, Austria
    Wien Klin Wochenschr 126:212-6. 2014
    The first case of human immunodeficiency virus type 2 (HIV-2) seropositivity in Austria was confirmed in 1993 in a dually human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected patient from Ghana, who died in 2001...
  101. doi [Use of a synthetic peptide of HIV-2 glycoprotein 36 in antigen mixtures for the immunodiagnosis of HIV types 1 and 2]
    Grisell Ramos Martínez
    Laboratorio de Retrovirus, Centro de Inmunoensayo, La Habana, Cuba
    Enferm Infecc Microbiol Clin 33:663-5. 2015
    The HIV-2 glycoprotein 36 (gp36) is often used in ELISA. An evaluation of the diagnostic indexes of antigen mixtures with a synthetic peptide of HIV2 gp36 (5) is performed in this study.

Research Grants11

  1. DEK EFFECTS ON GROWTH OF HEMATOPOIETIC CELLS
    Gerard Grosveld; Fiscal Year: 2002
    ..DEK binds to a sequence in the long terminal repeat (LTR) of human immunodeficiency virus type 2 and is essential for mitogen-induced transcription of the viral LTR in T cells and myeloid cells...
  2. LENTIVIRAL GENE TRANSFER INTO PANCREATIC BETA-CELLS
    Mark Segal; Fiscal Year: 2003
    ..of a cell line providing human immunodeficiency virus type 1 (HIV-1) packaging functions, a human immunodeficiency virus type 2 (HIV-2) transfer vector, and an envelope vector expressing the glycoprotein B (gB) envelope protein ..
  3. Vpr as a Mediator Proteasomal Degradation
    CARLOS M DE NORONHA; Fiscal Year: 2010
    ..of Vpr for primate entivirus infections is underscored by the observation that several of these viruses, including HIV2, have duplicated vpr to generate two open reading frames, vpr and vpx...
  4. PATHOGENESIS OF HIV ASSOC THROMBOTIC MICROANGIOPATHY
    CHARLES ALPERS; Fiscal Year: 2003
    ..Preliminary studies have shown that a proportion of macaques, when experimentally infected with HIV2, will develop thrombotic microangiopathy that is morphologically similar, if not identical, to human HIV-associated ..
  5. ANTIVIRAL/BIOACTIVE COMPOUNDS--SYNTHESIS AND CHEMISTRY
    ELIAS COREY; Fiscal Year: 1999
    ..Finally, new methodology which is needed in organic synthesis will be investigated, especially methods for enantioselective and catalytic synthesis. ..
  6. REGULATION OF HIV2 TRANSCRIPTION AND REPLICATION
    DAVID MARKOVITZ; Fiscal Year: 2002
    The replication of the human immunodeficiency viruses types 1 and 2 (HIV-1 and HIV-2) can be markedly suppressed in many patients, but the current therapies have not eradicated infection...
  7. HIV-1/HIV-2 EPITOPE PROJECT, THE GAMBIA, WEST AFRICA
    Anne De Groot; Fiscal Year: 2001
    ..As some HIV2-infected individuals appear to be resistant to HIV-1 infection, some have proposed that recognition of cross-..
  8. HIV-2--A MODEL OF HIV PRIMARY INFECTION
    Phyllis Kanki; Fiscal Year: 2002
    DESCRIPTION (adapted from the Abstract): Studies of HIV2-infected individuals have demonstrated a significantly slower progression to AIDS...
  9. INDUCTION OF APOPTOSIS BY HIV-1 VPR
    Vicente Planelles; Fiscal Year: 2010
    The HIV-1 accessory gene vpr encodes a conserved 96-amino acid protein that induces block of the cell cycle at the 62 phase. Expression of Vpr in CD4+ lymphocytes also induces apoptosis...
  10. Activation of a DNA damage pathway by HIV-1 vpr
    Vicente Planelles; Fiscal Year: 2003
    The human immunodeficiency virus type-1 (HIV-1) encodes four accessory genes that regulate various aspects of the host cell biology...
  11. Epidemiology of HIV-1/HIV-2 Dual Infection
    Geoffrey Gottlieb; Fiscal Year: 2005
    This application, entitled Molecular Epidemiology and Viral Evolution in HIV-2 and HIV-1/HIV-2 Dually Infected Individuals in Senegal, for a K08 Mentored Clinical Scientist Development Award, will help enable Dr. Geoffrey S...

Patents29

  1. METHODS FOR IDENTIFYING ANTIRETROVIRAL COMPOUNDS TARGETING THE REVERSE TRANSCRIPTASE OF HIV
    Patent Number: EP3088535-A1; Date:2016-11-02
  2. METHODS FOR IDENTIFYING ANTIRETROVIRAL COMPOUNDS TARGETING THE REVERSE TRANSCRIPTASE OF HIV
    Patent Number: WO2016173715-A1; Date:2016-11-03
  3. METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION
    Patent Number: EP3038661-A1; Date:2016-07-06
  4. METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION
    Patent Number: KR1020160060659-A; Date:2016-05-30
  5. METHODS FOR IMPROVING AND MANAGING NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITION BASED TREATMENT
    Patent Number: JP2014519321-A; Date:2014-08-14
  6. DETECTION OF NUCLEIC ACIDS USING UNMODIFIED GOLD NANOPARTICLES
    Patent Number: EP2694685-A1; Date:2014-02-12
  7. METHODS USING TRANSFORMED YEAST CELLS FOR IMPROVING AND MANAGING NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITION BASED TREATMENT
    Patent Number: WO2012156083-A1; Date:2012-11-22
  8. Compositions and methods for detecting human immunodeficiency virus 2 (hiv-2)
    Patent Number: WO0234951-A2; Date:2002-05-02
  9. Molecular scaffolds for hiv-1 immunogens
    Patent Number: WO2006091455-A2; Date:2006-08-31
  10. DNA EXHIBITING COMPLEMENTARITY TO GENE RNA OF HUMAN IMMUNODEFICIENCY VIRUS-2 TYPE
    Patent Number: JP1989289486-A; Date:1989-11-21
  11. VIRAL VECTORS
    Patent Number: JP2004526450-A; Date:2004-09-02
  12. Compositions and Methods for Detecting Human Immunodeficiency Virus 2 (HIV-2)
    Patent Number: JP2004518416-A; Date:2004-06-24
  13. Compositions and methods for diagnosing hiv-2 infection
    Patent Number: WO2007084021-A2; Date:2007-07-26
  14. Pseudotyping of foamy viruses
    Patent Number: EP2583974-A1; Date:2013-04-24
  15. Chimaeric vector system
    Patent Number: WO2005014836-A2; Date:2005-02-17
  16. METHODS FOR IMPROVING AND MANAGING NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITION BASED TREATMENT
    Patent Number: WO2012156086-A1; Date:2012-11-22
  17. Viral vectors
    Patent Number: WO02079464-A2; Date:2002-10-10
  18. Expression of peptides of the cytoplasmic domain of hiv-gp41 for inhibiting viral infections
    Patent Number: WO2004052924-A1; Date:2004-06-24
  19. Chimeric recombinant protein and in vitro diagnosis
    Patent Number: WO2004027066-A2; Date:2004-04-01
  20. Artificial double stranded nucleic acid containing bicyclic cytosine derivative
    Patent Number: JP2012179027-A; Date:2012-09-20
  21. METHODS FOR AMPLIFICATION OF GENOME AND MIXTURES OF INITIATOR OLIGONUCLEOTIDES FOR THE DETECTION AND IDENTIFICATION OF RELATED GENOMIC SEQUENCES
    Patent Number: WO9325707-A2; Date:1993-12-23
  22. RETROVIRUS OF THE HIV-2 TYPE SUSCEPTIBLE OF INDUCING AIDS, AND ITS ANTIGENIC AND NUCLEIC CONSTITUENTS
    Patent Number: WO8704459-A1; Date:1987-07-30
  23. HIV-2 virus variants
    Patent Number: EP0347365-A2; Date:1989-12-20
  24. Retrovirus of the type HIV-2, susceptible to provoke AIDS, and its antigenic and nucleic-acid constituents
    Patent Number: EP0269520-A2; Date:1988-06-01
  25. Retrovirus of the type HIV-2 capable of inducing AIDS, and the antigenic and nucleic acid components thereof
    Patent Number: EP0239425-A1; Date:1987-09-30
  26. Biologically active reverse transcriptases
    Patent Number: JP2002534125-A; Date:2002-10-15
  27. Vpr modulation and uses thereof
    Patent Number: WO03076621-A2; Date:2003-09-18
  28. Viral nucleic acid microarray and method of use
    Patent Number: WO2007130519-A2; Date:2007-11-15
  29. Nucleic acid detection method
    Patent Number: WO2009007743-A1; Date:2009-01-15